[1]
|
Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Xia, L., et al. (2019) PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. The Oncologist, 24, S31-S41. https://doi.org/10.1634/theoncologist.2019-IO-S1-s05
|
[3]
|
Miao, K., et al. (2022) Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China. Frontiers in Oncology, 12, Article 859938. https://doi.org/10.3389/fonc.2022.859938
|
[4]
|
Negrao, M.V., et al. (2021) Oncogene-Specific Differences in Tu-mor Mutational Burden, PD-L1 Expression, and Outcomes from Immunotherapy in Non-Small Cell Lung Cancer. Jour-nal for Immunotherapy of Cancer, 9, e002891.
https://doi.org/10.1136/jitc-2021-002891
|
[5]
|
Aguilar, E.J., et al. (2019) Outcomes to First-Line Pembrolizumab in Patients with Non-Small-Cell Lung Cancer and Very High PD-L1 Expression. Annals of Oncology, 30, 1653-1659. https://doi.org/10.1093/annonc/mdz288
|
[6]
|
Doroshow, D.B., et al. (2021) PD-L1 as a Biomarker of Response to Immune-Checkpoint Inhibitors. Nature Reviews. Clinical Oncology, 18, 345-362. https://doi.org/10.1038/s41571-021-00473-5
|
[7]
|
Bravaccini, S., et al. (2021) TMB in NSCLC: A Broken Dream? International Journal of Molecular Sciences, 22, Article 6536. https://doi.org/10.3390/ijms22126536
|
[8]
|
Li, S., et al. (2020) Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Frontiers in Immunology, 11, Article 603157.
https://doi.org/10.3389/fimmu.2020.603157
|
[9]
|
de Visser, K.E. and Joyce, J.A. (2023) The Evolving Tumor Mi-croenvironment: From Cancer Initiation to Metastatic Outgrowth. Cancer Cell, 41, 374-403. https://doi.org/10.1016/j.ccell.2023.02.016
|
[10]
|
Sharma, P., et al. (2017) Primary, Adaptive, and Acquired Re-sistance to Cancer Immunotherapy. Cell, 168, 707-723.
https://doi.org/10.1016/j.cell.2017.01.017
|
[11]
|
Daassi, D., et al. (2020) The Importance of Exosomal PDL1 in Tu-mour Immune Evasion. Nature Reviews. Immunology, 20, 209-215. https://doi.org/10.1038/s41577-019-0264-y
|
[12]
|
Niu, M., et al. (2022) Biological Characteristics and Clinical Sig-nificance of Soluble PD-1/PD-L1 and Exosomal PD- L1 in Cancer. Frontiers in Immunology, 13, Article 827921. https://doi.org/10.3389/fimmu.2022.827921
|
[13]
|
Murakami, S., et al. (2020) Association Between Serum Level Soluble Programmed Cell Death Ligand 1 and Prognosis in Patients with Non-Small Cell Lung Cancer Treated with An-ti-PD-1 Antibody. Thoracic Cancer, 11, 3585-3595. https://doi.org/10.1111/1759-7714.13721
|
[14]
|
Scirocchi, F., et al. (2022) Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 23, Article 14496.
https://doi.org/10.3390/ijms232214496
|
[15]
|
Morrissey, S.M. and Yan, J. (2020) Exosomal PD-L1: Roles in Tu-mor Progression and Immunotherapy. Trends in Cancer, 6, 550-558. https://doi.org/10.1016/j.trecan.2020.03.002
|
[16]
|
Kim, D.H., et al. (2019) Exosomal PD-L1 Promotes Tumor Growth through Immune Escape in Non-Small Cell Lung Cancer. Experimental & Molecular Medicine, 51, 1-13. https://doi.org/10.1038/s12276-019-0295-2
|
[17]
|
Li, C., et al. (2019) Clinical Significance of PD-L1 Expression in Serum-Derived Exosomes in NSCLC Patients. Journal of Translational Medicine, 17, Article No. 355. https://doi.org/10.1186/s12967-019-2101-2
|
[18]
|
Yang, Q., et al. (2021) Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients. Frontiers in Immunology, 12, Article 665133.
https://doi.org/10.3389/fimmu.2021.665133
|
[19]
|
Mazel, M., et al. (2015) Frequent Expression of PD-L1 on Cir-culating Breast Cancer Cells. Molecular Oncology, 9, 1773-1782. https://doi.org/10.1016/j.molonc.2015.05.009
|
[20]
|
Guibert, N., et al. (2018) PD-L1 Expression in Circulating Tu-mor Cells of Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Lung Cancer (Amsterdam, Netherlands), 120, 108-112.
https://doi.org/10.1016/j.lungcan.2018.04.001
|
[21]
|
Nicolazzo, C., et al. (2016) Monitoring PD-L1 Positive Circu-lating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with the PD-1 Inhibitor Nivolumab. Scientific Re-ports, 6, Article No. 31726.
https://doi.org/10.1038/srep31726
|
[22]
|
Indini, A., et al. (2021) Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. Cancers, 13, Article 1794.
https://doi.org/10.3390/cancers13081794
|
[23]
|
Strati, A., et al. (2023) Clinical Significance of PD-L1 Status in Cir-culating Tumor Cells for Cancer Management During Immunotherapy. Biomedicines, 11, Article 1768. https://doi.org/10.3390/biomedicines11061768
|
[24]
|
Hinterleitner, C., et al. (2021) Platelet PD-L1 Reflects Collec-tive Intratumoral PD-L1 Expression and Predicts Immunotherapy Response in Non-Small Cell Lung Cancer. Nature Communications, 12, Article No. 7005.
https://doi.org/10.1038/s41467-021-27303-7
|
[25]
|
Gandara, D.R., et al. (2018) Blood-Based Tumor Mutational Burden as a Predictor of Clinical Benefit in Non-Small- Cell Lung Cancer Patients Treated with Atezolizumab. Nature Medicine, 24, 1441-1448.
https://doi.org/10.1038/s41591-018-0134-3
|
[26]
|
Si, H., et al. (2021) A Blood-Based Assay for Assessment of Tumor Mutational Burden in First-Line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clinical Cancer Research, 27, 1631-1640.
https://doi.org/10.1158/1078-0432.CCR-20-3771
|
[27]
|
Kim, E.S., et al. (2022) Blood-Based Tumor Mutational Burden as a Biomarker for Atezolizumab in Non-Small Cell Lung Cancer: The Phase 2 B-F1RST Trial. Nature Medicine, 28, 939-945. https://doi.org/10.1038/s41591-022-01754-x
|
[28]
|
Stetson, D., et al. (2019) Orthogonal Comparison of Four Plasma NGS Tests with Tumor Suggests Technical Factors Are a Major Source of Assay Discordance. JCO Precision Oncology, 3, 1-9. https://doi.org/10.1200/PO.18.00191
|
[29]
|
Liu, Z., et al. (2019) Presence of Allele Frequency Heterogeneity Defined by CtDNA Profiling Predicts Unfavorable Overall Survival of NSCLC. Translational Lung Cancer Research, 8, 1045-1050.
https://doi.org/10.21037/tlcr.2019.12.10
|
[30]
|
Nie, W., et al. (2022) CtDNA-Adjusted BTMB as a Predictive Bi-omarker for Patients with NSCLC Treated with PD- (L)1 Inhibitors. BMC Medicine, 20, Article No. 170. https://doi.org/10.1186/s12916-022-02360-x
|
[31]
|
Hedrick, C.C. and Malanchi, I. (2022) Neutrophils in Cancer: Heterogeneous and Multifaceted. Nature Reviews. Immunology, 22, 173-187. https://doi.org/10.1038/s41577-021-00571-6
|
[32]
|
Gungabeesoon, J., et al. (2023) A Neutrophil Response Linked to Tumor Control in Immunotherapy. Cell, 186, 1448- 1464.e20. https://doi.org/10.1016/j.cell.2023.02.032
|
[33]
|
Tanizaki, J., et al. (2018) Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Thoracic Oncology, 13, 97-105.
https://doi.org/10.1016/j.jtho.2017.10.030
|
[34]
|
Saini, R. and Singh, S. (2019) Inducible Nitric Oxide Synthase: An Asset to Neutrophils. Journal of Leukocyte Biology, 105, 49-61. https://doi.org/10.1002/JLB.4RU0418-161R
|
[35]
|
Hirschhorn, D., et al. (2023) T Cell Immunotherapies Engage Neutrophils to Eliminate Tumor Antigen Escape Variants. Cell, 186, 1432-1447.e17. https://doi.org/10.1016/j.cell.2023.03.007
|
[36]
|
Cao, D., et al. (2018) A Reliable and Feasible Way to Predict the Benefits of Nivolumab in Patients with Non-Small Cell Lung Cancer: A Pooled Analysis of 14 Retrospective Studies. Oncoimmunology, 7, e1507262.
https://doi.org/10.1080/2162402X.2018.1507262
|
[37]
|
Chen, Y., et al. (2021) Association of Dynamic Changes in Peripheral Blood Indexes with Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients with Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 12, Article 672271. https://doi.org/10.3389/fimmu.2021.672271
|
[38]
|
Mezquita, L., et al. (2021) Predicting Immunotherapy Outcomes under Therapy in Patients with Advanced NSCLC Using DNLR and Its Early Dynamics. European Journal of Cancer (Oxford, England: 1990), 151, 211-220.
https://doi.org/10.1016/j.ejca.2021.03.011
|
[39]
|
Alessi, J.V., et al. (2021) Low Peripheral Blood Derived Neutro-phil-to-Lymphocyte Ratio (DNLR) Is Associated with Increased Tumor T-Cell Infiltration and Favorable Outcomes to First-Line Pembrolizumab in Non-Small Cell Lung Cancer. Journal for Immunotherapy of Cancer, 9, e003536. https://doi.org/10.1136/jitc-2021-003536
|
[40]
|
Li, Y., et al. (2020) Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors (ICIs). Frontiers in Oncology, 10, Article 654. https://doi.org/10.3389/fonc.2020.00654
|
[41]
|
Holtzman, L., et al. (2022) dNLR-Based Score Predicting Overall Survival Benefit for the Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC with PD-L1 Tumor Proportion Score ≥ 50. Clinical Lung Cancer, 23, 122-134. https://doi.org/10.1016/j.cllc.2021.12.006
|
[42]
|
Diem, S., et al. (2017) Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab. Lung Cancer (Amsterdam, Netherlands), 111, 176-181. https://doi.org/10.1016/j.lungcan.2017.07.024
|
[43]
|
Zheng, L., et al. (2023) Decreased Monocyte-to-Lymphocyte Ratio Was Associated with Satisfied Outcomes of First-Line PD-1 Inhibitors Plus Chemotherapy in Stage IIIB-IV Non-Small Cell Lung Cancer. Frontiers in Immunology, 14, Article 1094378. https://doi.org/10.3389/fimmu.2023.1094378
|
[44]
|
Ma, C., et al. (2022) Platelets Control Liver Tumor Growth through P2Y12-Dependent CD40L Release in NAFLD. Cancer Cell, 40, 986-998.e5. https://doi.org/10.1016/j.ccell.2022.08.004
|
[45]
|
Pankowska, K.A., et al. (2023) Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance. International Journal of Molecular Sciences, 24, Article 9279.
https://doi.org/10.3390/ijms24119279
|
[46]
|
Zhang, G., et al. (2022) Clinical Predictive Value of Naïve and Memory T Cells in Advanced NSCLC. Frontiers in Immunology, 13, Article 996348. https://doi.org/10.3389/fimmu.2022.996348
|
[47]
|
Wang, Y.-Y., et al. (2020) Circulating Activated Lymphocyte Subsets as Potential Blood Biomarkers of Cancer Progression. Cancer Medicine, 9, 5086-5094. https://doi.org/10.1002/cam4.3150
|
[48]
|
Huang, A.C., et al. (2017) T-Cell Invigoration to Tumour Burden Ratio Associated with Anti-PD-1 Response. Nature, 545, 60-65. https://doi.org/10.1038/nature22079
|
[49]
|
Nabet, B.Y., et al. (2020) Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 183, 363-376.e13. https://doi.org/10.1016/j.cell.2020.09.001
|
[50]
|
Kim, K.H., et al. (2019) The First-Week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clini-cal Cancer Research, 25, 2144-2154.
https://doi.org/10.1158/1078-0432.CCR-18-1449
|
[51]
|
Han, J., et al. (2020) TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. Cancer Immunology Research, 8, 146-154.
https://doi.org/10.1158/2326-6066.CIR-19-0398
|
[52]
|
Borst, J., et al. (2018) CD4+ T Cell Help in Cancer Immu-nology and Immunotherapy. Nature Reviews. Immunology, 18, 635-647. https://doi.org/10.1038/s41577-018-0044-0
|
[53]
|
Kruse, B., et al. (2023) CD4+ T Cell-Induced Inflammatory Cell Death Controls Immune-Evasive Tumours. Nature, 618, 1033-1040. https://doi.org/10.1038/s41586-023-06199-x
|
[54]
|
Miao, K., et al. (2022) Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Immunology, 13, Ar-ticle 912180.
https://doi.org/10.3389/fimmu.2022.912180
|
[55]
|
戴斌, 黄翠萍, 曹喆, 等. PD-1抑制剂对晚期非小细胞肺癌患者T淋巴细胞亚群、NK细胞及抑制性免疫检查点的影响[J]. 中国老年学杂志, 2021, 41(7): 1393-1396.
|
[56]
|
Sui, H., et al. (2022) Immunotherapy of Targeting MDSCs in Tumor Microenvironment. Frontiers in Immunology, 13, Arti-cle 990463. https://doi.org/10.3389/fimmu.2022.990463
|
[57]
|
Youn, J.-I., et al. (2020) Peripheral Natural Killer Cells and Myeloid-Derived Suppressor Cells Correlate with Anti-PD-1 Responses in Non-Small Cell Lung Cancer. Sci-entific Reports, 10, Article No. 9050.
https://doi.org/10.1038/s41598-020-65666-x
|
[58]
|
Kim, H.R., et al. (2019) The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-Derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Ther-apy in Patients with Non-Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 199, 243-246.
https://doi.org/10.1164/rccm.201808-1502LE
|
[59]
|
Sanmamed, M.F., et al. (2017) Changes in Serum Interleukin-8 (IL-8) Levels Reflect and Predict Response to Anti-PD-1 Treatment in Melanoma and Non-Small-Cell Lung Cancer Pa-tients. Annals of Oncology, 28, 1988-1995.
https://doi.org/10.1093/annonc/mdx190
|
[60]
|
Keegan, A., et al. (2020) Plasma IL-6 Changes Correlate to PD-1 In-hibitor Responses in NSCLC. Journal for Immunotherapy of Cancer, 8, e000678. https://doi.org/10.1136/jitc-2020-000678
|
[61]
|
Riedl, J.M., et al. (2020) C-Reactive Protein (CRP) Levels in Im-mune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. Cancers, 12, Article 2319.
https://doi.org/10.3390/cancers12082319
|
[62]
|
Klümper, N., et al. (2022) C Reactive Protein Flare Predicts Re-sponse to Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer. Journal for Immunotherapy of Cancer, 10, e004024. https://doi.org/10.1136/jitc-2021-004024
|
[63]
|
Mezquita, L., et al. (2018) Association of the Lung Im-mune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 4, 351-357.
https://doi.org/10.1001/jamaoncol.2017.4771
|
[64]
|
Madeddu, C., et al. (2023) Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. Cancers, 15, Article 1076. https://doi.org/10.3390/cancers15041076
|